Search Results

You are looking at 111 - 120 of 487 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Charu Aggarwal, Neeta Somaiah, and George R. Simon

carcinoma, and large cell carcinoma histologies. Early-stage NSCLC represents a minority of cases and is often curable with surgery with or without adjuvant chemotherapy. Radiation therapy, surgery, and chemotherapy have been used alone or in combination to

Full access

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

-specific survival advantage over postoperative adjuvant chemotherapy in patients with stage II tumors. NSABP B-27 was a 3-arm, randomized, phase III trial of women with invasive breast cancer treated with preoperative systemic therapy with AC (doxorubicin

Full access

Robin K. Kelley, Grace Wang, and Alan P. Venook

, his oncologist requests MMR protein testing of his tumor specimen to inform decision-making regarding adjuvant chemotherapy. His tumor is found to have deficiency in MLH1 through immunohistochemistry along with high-level MSI (MSI-H) according to PCR

Full access

John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick

based on prior studies of adjuvant chemotherapy, 15 and the criteria now include results of axial imaging, examination under anesthesia, and TUR. Specifically, MD Anderson defines high-risk disease as the presence of a palpable mass or local invasion

Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah Freedman-Cass

rates were seen, and induction chemotherapy seemed to be less toxic and better tolerated. Another phase II trial randomized patients to chemoRT and surgery with or without FOLFOX induction therapy; adjuvant chemotherapy was administered at the

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

, and patients aged 50 to 69 years received less benefit from chemotherapy than patients younger than 50 years. 108 In addition, the benefit of adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil) in addition to tamoxifen

Full access

Huei-Ting Tsai, Claudine Isaacs, Filipa C. Lynce, Suzanne C. O'Neill, Chunfu Liu, Marc D. Schwartz, Nandini Selvam, Yingjun Zhou, and Arnold L. Potosky

combination with cytotoxic chemotherapies. 1 In January 2008, trastuzumab was approved for use as single-agent therapy after standard adjuvant chemotherapy for early-stage, HER2-positive breast cancer, independent of nodal status, based on data from the

Full access

Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou, and Elizabeth Bayliss

patients have a median time of 69 days to starting RT after their last surgery when no other adjuvant chemotherapy was indicated. The process of external referral to radiation oncology adds significantly to the delay (median of 22 days from referral to

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

micrometastases to the bone marrow: a long-term follow-up . Ann Oncol 2008 ; 19 : 2007 – 2011 . 13. Coleman R Thorpe H Cameron D . Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy—first safety data from the

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

axillary lymph nodes; and, to a lesser extent, presence or absence of estrogen receptor (ER) and progesterone receptor (PR). In this paradigm, clinicians estimated the risk of recurrence and, if it was large enough, provided adjuvant chemotherapy and—if the